Beranda › Kanker Ginjal (Karsinoma Sel Renal) › Oregon › Portland
Uji klinis Kanker Ginjal (Karsinoma Sel Renal) di Portland, OR
11 studi untuk Kanker Ginjal (Karsinoma Sel Renal) mencari peserta di lokasi sekitar Portland (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Providence Willamette Falls Medical Center, Oregon City · 12 mi jauhnya
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Menerima pesertaFase 1
- Exelixis Clinical Site #51, Portland
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Menerima pesertaFase 2
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Menerima pesertaFase 1/2
- Northwest Cancer Specialists, P.C., Portland
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Menerima pesertaFase 3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
- dan 1 lainnya
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Menerima pesertaFase 1/2
- Providence Cancer Center Oncology and Hematology Care- Eastside, Portland
A Study of MGC026 in Participants With Advanced Solid Tumors
Menerima pesertaFase 1
- Providence Cancer Institute, Portland
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
Menerima pesertaFase 1/2
- Oregon Health & Science University (3485 S. Bond), Portland
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
Menerima pesertaFase 4
- OHSU Knight Cancer Institute, Portland
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Menerima pesertaFase 1
- Oregon Health & Science University, Portland
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
Menerima pesertaFase 3
- Kaiser Permanente Northwest, Portland
- Oregon Health and Science University, Portland
Uji klinis Kanker Ginjal (Karsinoma Sel Renal) di kota lain
- Houston, TX35 studi
- New York City, NY27 studi
- Dallas, TX23 studi
- Nashville, TN23 studi
- St. Louis, MO23 studi
- Los Angeles, CA20 studi
- Boston, MA16 studi
- Baldwin Park, CA16 studi
- Pittsburgh, PA15 studi
- Philadelphia, PA15 studi
- Queens, NY15 studi
- Jacksonville, FL14 studi
Studi lain di Portland
- Kanker Paru Non-Sel Kecil46 studi
- Kanker (semua jenis)34 studi
- Kanker Payudara33 studi
- Kanker Prostat33 studi
- Kanker Metastatik29 studi
- Kanker Kolorektal28 studi
- Kanker Ovarium27 studi
- Kanker Paru26 studi
- Leukemia Mieloid Akut25 studi
- Kanker Endometrium24 studi
- Karsinoma Sel Skuamosa Kepala dan Leher19 studi
- Kanker Pankreas19 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.